

## IN THE CLAIMS

Please replace prior versions and listings of claims in the application with the following set of claims beginning on page 3 that follows.

Claims 52 and 53 have been merged into the amended claim 53, which is now written as an independent claim and pertains to all the antimetabolites referenced in the original specification.

Claim 75, that provides a special subset of the claimed generic composition, and claim 91 that provides the method of making the generic composition are written as independent claims and amended to include all the antimetabolites referenced in the specification as well.

Applicants trust, however, that the generic claims 51, 74 and 89 will be found allowable in view of the remarks and documentation submitted herewith. Therefore the sets of dependent claims from these generic claims have been retained in this amendment.

Claims 52 and 90 are canceled. Claim 92 is added.


Claims 1-37 stand canceled; Claims 38-44 had previously been withdrawn, with traverse, in response to the restriction requirement; and Claims 45-50 were canceled in the previous amendment.

No new matter has been introduced by this amendment.

## CLAIMS

1-37 (Canceled)

38. (Withdrawn) A compound having purity in excess of 98% by HPLC, having the formula:



wherein  $\text{R}$  is selected from the group consisting of  $\text{H}$ , a C1-C6 alkyl, a halogen, a C2-C6 alkenyl, and a C2-C6 alkynyl;


$\text{x}$  is an amine-protecting group that is stable in oligonucleotide synthesis conditions; and  $\text{y}$ , and  $\text{z}$  are each selected from  $\text{H}$ , a hydroxyl-protecting group that is stable in oligonucleotide synthesis conditions and a group that can be attached to a solid support.

39. (Withdrawn) The compound of claim 23, wherein the group that is attachable to a solid

support has the formula  $O-C(=O)-M-C(=O)-NH\text{-Spacer}$ , where M is selected from the group consisting of succinyl, oxalyl, and hydroquinolynyl, and wherein the Spacer is selected from the

40. (Withdrawn) group consisting of a C1-C6 alkyl, ethoxyglycol, and a combination of alkyl and ethyleneglycoxy.

41. (Withdrawn) A compound having the formula:




wherein R is selected from the group consisting of H, a C1-C6 alkyl, a halogen, a C2-C6 alkenyl, and a C2-C6 alkynyl;

x is an amine-protecting group that is stable in oligonucleotide synthesis conditions;

z is a hydroxyl-protecting group that is stable in oligonucleotide synthesis conditions; and  
n is 2-20.

42. (Withdrawn) A compound of the formula:




wherein R is selected from the group consisting of H, a C1-C6 alkyl, a halogen, a C2-C6 alkenyl, and a C2-C6 alkynyl;

x is an amine-protecting group that is stable in oligonucleotide synthesis conditions;

z is a hydroxyl-protecting group that is stable in oligonucleotide synthesis conditions; and  
n is 2-20.

43. (Withdrawn) A compound having a purity in excess of 97% by HPLC, as shown by the  
the  
formula:




wherein y is a hydroxyl-protecting group that is stable in oligonucleotide synthesis conditions;

x is an amine-protecting group that is stable in oligonucleotide synthesis conditions;

R is selected from the group consisting of H, a C1-C6 alkyl, a halogen, a C2-C6 alkenyl, and a C2-C6 alkynyl; and

R' and R'' are independently selected from the group consisting of a C1-C6 alkyl and a C2-C6 cycloalkyl.

44. (Withdrawn) A compound having purity in excess of 97 % by HPLC, and having the formula:



wherein y is a hydroxyl-protecting group that is stable in oligonucleotide synthesis conditions;

x is an amine-protecting group that is stable in oligonucleotide synthesis conditions;

R is selected from the group consisting of H, a C1-C6 alkyl, a halogen, a C2-C6 alkenyl, and a C2-C6 alkynyl; and

R' and R'' are independently selected from the group consisting of a C1-C6 alkyl and a C2-C6 cycloalkyl.

45. – 50. (Canceled)

51. (Previously presented) An oligonucleotide for preferentially killing cancerous cells over noncancerous cells comprising at least two CpG moieties and a nucleoside antimetabolite covalently linked to the oligonucleotide.

52. (Canceled)